AbbVie has extended its status as a Dividend King with 54 consecutive years of annual dividend increases, reflecting a deeply entrenched commitment to shareholder returns. The company currently offers a 2.98% dividend yield, supported by a robust balance sheet and approximately $10 billion in free cash flow generated in the trailing twelve months. This record of consistency positions AbbVie among a select group of healthcare companies that have demonstrated both resilience through economic cycles and the financial capacity to sustain and grow payouts over more than half a century.

Once heavily reliant on Humira, which saw sales decline by roughly 28% year-over-year in 2025 due to biosimilar competition, AbbVie has successfully rebalanced its portfolio. Key launches Rinvoq and Skyrizi now account for over $15 billion in combined annual revenue run-rate. Rinvoq grew approximately 51% year-over-year in the fourth quarter, driven by expansion into new indications, while Skyrizi posted a 42% gain amid strong uptake in both dermatology and rheumatology. Management forecasts these two franchises to deliver mid-teens percentage revenue growth in 2026, effectively offsetting Humira’s erosion and underpinning long-term earnings power.

Entering the fourth-quarter earnings release, AbbVie’s shares trade at an estimated 15% discount to the average peer healthcare multiple, a gap attributed to concerns over Humira’s decline and overall macro uncertainty. Analysts expect AbbVie to report total revenues of roughly $14.8 billion for the period, with non-GAAP EPS projected near $3.05. Investors will closely watch margin expansion from operating efficiencies, guidance for free cash flow exceeding $11 billion next year, and any commentary on potential share buyback authorizations. A reaffirmation of dividend growth guidance and confirmation of the Rinvoq/Skyrizi trajectory could catalyze a valuation re-rating if management maintains or strengthens its outlook.